Human CXCR3 Full Length Protein (VLP)

Chemokines are proteins which induce chemotaxis, promote differentiation of immune cells, and cause tissue extravasation. Given these properties, their role in anti-tumor immune response in the cancer environment is of great interest. Although immunotherapy has shown clinical benefit for some cancer patients, other patients do not respond. One of the mechanisms of resistance to checkpoint inhibitors may be chemokine signaling. The CXCL9, -10, -11/CXCR3 axis regulates immune cell migration, differentiation, and activation, leading to tumor suppression (paracrine axis) . However, there are some reports that show involvements of this axis in tumor growth and metastasis (autocrine axis) . Thus, a better understanding of CXCL9, -10, -11/CXCR3 axis is necessary to develop effective cancer control.

Product Specifications

Background

Specifications

This protein .

Accession Number

P49682-1

Expression Region

Val 2 - Leu 368

Host

HEK293

Target

CXCR3

Conjugation

Unconjugated

Source

Human

Stability

The product MUST be stored at -70°C or lower upon receipt; -70°C for 12 months under sterile conditions.

Endotoxin

1.0 EU per μg

Bioactivity

Immobilized Human CXCR3 Full Length Protein-VLP (Cat. No. CX3-H52P4) at 5 μg/mL (100 μL/well) can bind Anti-CXCR3 Antibody, Human IgG1 with a linear range of 0.8-6 ng/mL (QC tested).